Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400097 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL17451842 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL29132902 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL17453181 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL13242445 | 1.00 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL2742456 | 0.86 | CA1 (0.39) | CA1CA2CA12CA9PPM1B | |
| SCHEMBL12357210 | 0.85 | PPM1B (0.39) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL2127524 | 0.85 | PPM1B (0.39) | LMNAPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL1128162 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA | |
| SCHEMBL30158792 | 0.84 | CA1 (0.38) | CA1CA2CA12CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | US | claimed |
| WO-2024211274-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | NOHMs Technologies, Inc. (US) | 2024-10-10 | — | — | WO | claimed |
| CN-113956157-B | Method for synthesizing ethyl 2-formyl-1-cyclopropanecarboxylate | 西安都创医药科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-113929578-B | Method for synthesizing ethyl 2-formyl-1-cyclopropanecarboxylate | 西安都创医药科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-113956157-A | Method for synthesizing 2-formyl-1-cyclopropane ethyl formate | 西安都创医药科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-113929578-A | Method for synthesizing 2-formyl-1-cyclopropane ethyl formate | 西安都创医药科技有限公司 | 2022-01-14 | — | — | CN | claimed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382300-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12466831-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3883575-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-116120384-B | Oligonucleotide-alpha-hydroxy phosphonic acid compound and synthesis method thereof | 康龙化成(宁波)科技发展有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-0003866-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-11-04 | — | — | EP | disclosed |
| US-4272437-A | PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1981-06-09 | — | — | US | disclosed |
| US-4222936-A | HERBICIDES | SHELL OIL COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
| US-4217283-A | 3-Azabicyclo(3.1.0)hexan-4-one-2-carbonitrile | SHELL OIL COMPANY (US) | 1980-08-12 | — | — | US | disclosed |
| EP-0004107-A1 | 3-Azabicyclo(3.1.0)hexane derivatives, a process for their preparation, biologically active compositions containing them and herbicidal method using them | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1979-09-19 | — | — | EP | disclosed |
| EP-0003866-A1 | 3-Azabicyclo(3.1.0)hexane derivatives and a process for their preparation | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1979-09-05 | — | — | EP | disclosed |
| US-4018798-A | Substituted (4-oxo-4H-1-benzopyran-2-yl)cyclopropane carboxylic acids and esters | WARNER-LAMBERT COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382300-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2B, ADORA2A, ADORA3 | CA1 3746/4885CA2 1421/4885CA12 4149/4885 |
| US-12466831-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | CA1 3709/4885CA2 1316/4885CA12 4084/4885 |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, RAD1, CHEK2 | CA1 2028/4885CA2 2343/4885CA12 2793/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | CA1 3990/4885CA2 2741/4885CA12 4184/4885 |
| US-20240339662-A1 | FUNCTIONALIZED CYCLIC ETHERS FOR LITHIUM-ION BATTERIES | SELE, CYCS, EPCAM | CA1 474/4885CA2 1240/4885CA12 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.